BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28593420)

  • 1. Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection?
    Ito H; Nakayama H; Murakami S; Yokose T; Katayama K; Miyata Y; Okada M
    Gen Thorac Cardiovasc Surg; 2017 Sep; 65(9):512-518. PubMed ID: 28593420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
    Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
    Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indications for sublobar resection of clinical stage IA radiologic pure-solid lung adenocarcinoma.
    Hattori A; Matsunaga T; Takamochi K; Oh S; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1100-1108. PubMed ID: 28629842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.
    Kadota K; Villena-Vargas J; Yoshizawa A; Motoi N; Sima CS; Riely GJ; Rusch VW; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2014 Apr; 38(4):448-60. PubMed ID: 24472852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma.
    Hung JJ; Jeng WJ; Chou TY; Hsu WH; Wu KJ; Huang BS; Wu YC
    Ann Surg; 2013 Dec; 258(6):1079-86. PubMed ID: 23532112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.
    Yoshizawa A; Motoi N; Riely GJ; Sima CS; Gerald WL; Kris MG; Park BJ; Rusch VW; Travis WD
    Mod Pathol; 2011 May; 24(5):653-64. PubMed ID: 21252858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by 2 staging systems: A North American experience.
    Wilshire CL; Louie BE; Horton MP; Castiglioni M; Aye RW; Farivar AS; West HL; Gorden JA; Vallières E
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1561-8. PubMed ID: 26897242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography.
    Nakamura H; Saji H; Shinmyo T; Tagaya R; Kurimoto N; Koizumi H; Takagi M
    Lung Cancer; 2015 Jan; 87(1):28-33. PubMed ID: 25481488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification.
    Zhang J; Wu J; Tan Q; Zhu L; Gao W
    J Thorac Oncol; 2013 Sep; 8(9):1196-202. PubMed ID: 23945388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes following lobectomy, segmentectomy, and wedge resection based on pathological subtyping in patients with pN0 invasive lung adenocarcinoma ≤1 cm.
    Song W; Hou Y; Zhang J; Zhou Q
    Cancer Med; 2022 Dec; 11(24):4784-4795. PubMed ID: 35570370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant difference in recurrence according to the proportion of high grade patterns in stage IA lung adenocarcinoma.
    Jeon HW; Kim YD; Sim SB; Moon MH
    Thorac Cancer; 2021 Jul; 12(13):1952-1958. PubMed ID: 34037324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.
    Eguchi T; Kadota K; Park BJ; Travis WD; Jones DR; Adusumilli PS
    Semin Thorac Cardiovasc Surg; 2014; 26(3):210-22. PubMed ID: 25527015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second predominant subtype predicts outcomes of intermediate-malignant invasive lung adenocarcinoma†.
    Ito M; Miyata Y; Yoshiya T; Tsutani Y; Mimura T; Murakami S; Ito H; Nakayama H; Okada M
    Eur J Cardiothorac Surg; 2017 Feb; 51(2):218-222. PubMed ID: 28186287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients.
    Cox ML; Yang CJ; Speicher PJ; Anderson KL; Fitch ZW; Gu L; Davis RP; Wang X; D'Amico TA; Hartwig MG; Harpole DH; Berry MF
    J Thorac Oncol; 2017 Apr; 12(4):689-696. PubMed ID: 28082103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters.
    Takahashi M; Shigematsu Y; Ohta M; Tokumasu H; Matsukura T; Hirai T
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):54-9. PubMed ID: 24131786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiologic findings to predict low-grade malignant tumour among clinical T1bN0 lung adenocarcinomas: lessons from histological subtypes.
    Mimae T; Miyata Y; Mimura T; Ito H; Nakayama H; Okumura S; Yoshimura M; Okada M
    Jpn J Clin Oncol; 2015 Aug; 45(8):767-73. PubMed ID: 26056324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma.
    Nakagiri T; Sawabata N; Morii E; Inoue M; Shintani Y; Funaki S; Okumura M
    Gen Thorac Cardiovasc Surg; 2014 Nov; 62(11):671-7. PubMed ID: 24890089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.
    Ujiie H; Kadota K; Chaft JE; Buitrago D; Sima CS; Lee MC; Huang J; Travis WD; Rizk NP; Rudin CM; Jones DR; Adusumilli PS
    J Clin Oncol; 2015 Sep; 33(26):2877-84. PubMed ID: 26261257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
    Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival.
    Hung JJ; Yeh YC; Jeng WJ; Wu KJ; Huang BS; Wu YC; Chou TY; Hsu WH
    J Clin Oncol; 2014 Aug; 32(22):2357-64. PubMed ID: 24799473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.